p-Aminosalicylic acid (PAS) conjugated to maleylated bovine serum albumin (MBSA) was taken up efficiently through high-affinity MBSA-binding sites on macrophages. Binding of the radiolabeled conjugate to cultured mouse peritoneal macrophages at 4°C was competed for by MBSA but not by PAS. At 37°C, the radiolabeled conjugate was rapidly degraded by the macrophages, leading to release of acid-soluble degradation products in the medium. The drug conjugate was nearly 100 times as effective as free PAS in killing the intracellular mycobacteria in mouse peritoneal macrophages infected in culture with Mycobacterium tuberculosis. The killing of intracellular mycobacteria mediated by the drug conjugate was effectively prevented by simultaneous addition of excess MBSA (100 ,ug/mI) or chloroquine (3 ,uM) to the medium, whereas these agents did not affect the microbicidal action of free PAS. These results suggest that (i) uptake of the PAS-MBSA conjugate was mediated by cell surface receptors on macrophages which recognize MBSA and (ii) lysosomal hydrolysis of the internalized conjugate resulted in intracellular release of a pharmacologically active form of the drug, which led to selective killing of the M. tuberculosis harbored by mouse macrophages infected in culture. This receptor-mediated modality of delivering drugs to macrophages could contribute to greater therapeutic efficacy and minimization of toxic side effects in the management of tuberculosis and other intracellular mycobacterial infections.
Mycobacterium tuberculosis owes its pathogenicity to its ability to survive and proliferate within mononuclear phagocytes (5) . It is estimated that every year about 10 million persons develop tuberculosis and at least 3 million die from the disease (16) . The most important factor in the treatment of tuberculosis is prolonged chemotherapy, which is often associated with serious unwanted side effects (7, 24) . In the chemotherapy of such intracellular pathogens, it is necessary to achieve relatively high levels of the drug in blood to attain therapeutically effective concentrations in infected cells, which presumably leads to adverse effects on healthy tissues. The present challenge in the therapy of intracellular infections, therefore, is to develop systems capable of delivering the drugs to the intracellular sites of action at relatively low levels in blood (reviewed in reference 6). Multilamellar liposomes are being explored for intracellular delivery of antimicrobial drugs (1, 4, 20) because of their preferential uptake by reticuloendothelial cells with various degrees of success. Recently, we have developed an alternative approach for selective intracellular delivery of drugs to macrophages (3, 15) by using endocytosis of macromolecular drug conjugates mediated presumably by scavenger receptors (2, 10, 17) present only on macrophages (and, to a lesser extent, on some endothelial cells). We have shown that effective chemotherapy of experimental leishmaniasis in hamsters can be achieved by homing an antileishmanial drug, methotrexate, to macrophages by using maleylated bovine serum albumin (MBSA) as the carrier to which the drug was chemically conjugated (3, 15) . In this study, we investigated the possibility of using MBSA as a vehicle for intracellular delivery of an antimycobacterial drug, p-aminosalicylic acid (PAS), to cultured mouse peritoneal macro-phages infected with M. tuberculosis. We chose PAS as the targeted drug to determine whether the receptor-mediated modality of uptake of the drug reported here is likely to be effective at lower dosages so that the toxic side reactions of this potent antimycobacterial agent, and the drug of choice until the 1970s, could be reduced to currently acceptable levels (14) .
MATERIALS AND METHODS
Organism. M. tuberculosis H37Ra obtained from N. K. Ganguly, Postgraduate Institute of Medical Education and Research, Chandigarh, India, was cultivated at 37°C for 7 days in Middlebrook 7H9 medium (Difco) containing Tween 80 and ADC enrichment. Bacteria were harvested in the exponential growth phase. CFU were counted by serial dilution on 7H10 agar plates (18) . Cells were preserved in 1-ml aliquots at -70°C, thawed just before use, and subjected to mild sonication to get single-cell suspensions.
Isolation of mouse peritoneal macrophages. Five-milliliter volumes of heparinized phosphate-buffered saline (PBS) were injected into the peritoneal cavities of BALB/c mice weighing 30 to 40 g. The peritoneal fluids from 15 mice were pooled, and the cells were collected by centrifugation (250 x g, 10 min, room temperature). Cells were suspended in medium A (RPMI 1640 medium [GIBCO] containing 10% heat-inactivated fetal calf serum, 2 g of sodium bicarbonate per liter, 2 mM glutamine, and 100 U of penicillin G per ml). One-milliliter aliquots of the cell suspension (2 x 106 cells per ml) were dispensed into six-well tissue culture clusters (Costar, Cambridge, Mass.) containing 1 ml of medium A and incubated at 37°C for 1 h in a humidified incubator containing 5% CO2. Nonadherent cells were removed by washing three times with sterile PBS. The monolayers were incubated for 24 To prepare the drug conjugate, MBSA was allowed to react with the sodium salt of PAS (Sigma) at pH 7.4 in the presence of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (Sigma) as previously described (8) . Briefly, three reactants, MBSA, PAS, and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide were mixed at a molar ratio of 1:60:60, respectively, in 3 ml of PBS and allowed to react for S h at room temperature with constant shaking. The conjugate was separated from other low-molecular-weight components by Sephadex 0-50 gel filtration, dialyzed against PBS, and stored frozen at -200C in small aliquots.
The amount of PAS bound to MBSA was determined by fluorescence measurement in a KONTRON SFM-25 spectrofluorometer with 310 nm as the excitation wavelength and 405 nm as the emission wavelength. PAS showed a characteristic fluorescence spectrum at this range (22) , but MBSA did not (data not shown). Protein concentration was determined by the biuret method. The molar ratio of PAS to MBSA was 33:1.
Radioiodination of PAS-MBSA conijugate. The PAS-MBSA conjugate was radioiodinated with Nal25I (Bhabha Atomic Research Centre, Bombay, India) by the iodine monochloride method as previously described (9) . The specific activity of the labeled product was about 600 cpm/ng of protein.
Binding of [1251] PAS-MBSA to peritoneal macrophages at 4°C. Macrophage monolayers prepared in six-well tissue culture clusters as described earlier were washed twice with ice-cold PBS. Each well received 1 ml of medium B (RPMI 1640 medium without bicarbonate and fetal calf serum but containing 1 mg of bovine serum albumin per ml) and the concentrations of [1251]PAS-MBSA indicated (see Fig. 1 ).
The clusters were incubated at 4°C with gentle shaking. After 2 h, the monolayers were washed three times with ice-cold PBS containing bovine serum albumin (1 mg/ml) and once with PBS. The cells were dissolved in 1 ml of 0.1 N NaOH, and radioactivity was measured by placing an aliquot in a gamma counter. Cellular protein content Was measured by using alkaline copper reagent as previously described (9) . clusters were incubated at 37°C in a humidified incubator containing 5% CO2 for 5 h or various other periods. The amounts of trichloroacetic acid-soluble degradation products released in the medium were estimated as previously described (9) . The monolayers were washed, and cell-associated radioactivity and protein content were determined as described above.
Infection of macrophage monolayers with M. tuberculosis. Monolayers prepared as described above were washed twice with PBS and incubated in a humidified incubator containing 5% CO2 with 2 ml of RPMI containing 1% fetal calf serum.
After 1 h, 1 ml of medium was withdrawn from each well and replaced with 1 ml of a suspension of M. tuberculosis H37Ra (107 cells per ml) grown as described earlier. After incubation at 37°C for 4 h, the monolayers were washed twice with PBS to remove extracellular bacteria. Ziehl-Neelsen staining of the monolayers showed the presence of 9 to 12 bacteria per macrophage. Each monolayer then received 2 ml of medium A and was incubated further at 37°C for 24 h.
Infected monolayers thus prepared were used to determine the effects of drugs.
Drug action against intracellular growth of phagocytosed mycobacteria. The concentrations of free PAS or PAS-MBSA indicated (see Fig. 5 ) were added to each infected monolayer prepared as described above, and incubation was continued for 4 h at 37°C. Monolayers were washed three times with PBS and incubated for 48 h in drug-free medium A. The macrophages were then lysed by adding 2.5% (wt/ vol) sodium dodecyl sulfate (SDS), and appropriate dilutions were plated on Middlebrook 7H10 agar as previously described (18) . CFU were counted after 3 weeks of incubation at 37°C. SDS did not affect the viability or growth of bacteria, as shown by control experiments (data not shown).
For determination of the time course of killing of M. tuberculosis H37Ra by PAS-MBSA conjugate or free PAS, infected monolayers (prepared as described earlier) were incubated with 2 jig of PAS per ml in free or conjugated form in medium A for various periods, washed, and incubated for up to 48 h at 37°C in drug-free medium A. The cells were lysed with SDS, and CFU were counted as described earlier.
RESULTS
Binding of [12SIJPAS-MBSA by peritoneal macrophages. To determine the nature of the interaction of PAS-MBSA with peritoneal macrophages, macrophage monolayers were incubated at 4°C with increasing concentrations of the labeled conjugate for 2 h, and after thorough washing, the radioactivity associated with the cells was measured. The experiments were done at 4°C to minimize the endocytic activities of the macrophages so that the cell-associated radioactivity largely reflects the binding of the ligand to discrete sites on the cell surface. Binding of [1251]PAS-MBSA to the cells followed saturation kinetics, indicating a limited number of binding sites for the ligand (Fig. 1) . Half-maximal binding occurred at a concentration of about 1 ,ug of the labeled conjugate per ml. Binding of radiolabeled PAS-MBSA was inhibited by free MBSA (half-maximal inhibition occurred at about 10 to 12 ,ug of MBSA per ml), but free PAS did not affect binding of the drug conjugate (Fig. 2) . Addition of unlabeled PAS-MBSA to the medium eliminated binding of (Fig. 3) . Half-maximal saturation for uptake, as well as degradation, of radiolabeled PAS-MBSA was achieved at a conjugate concentration of about 6 jig of protein per ml.
The data in Fig. 4 for various times, cellular radioactivity reached a steadystate plateau after about 2 h but acid-soluble radioactivity continued to appear in the medium linearly, reflecting con- under the same conditions eliminated only 12.5% of the mycobacteria. The superior antimycobacterial activity of PAS-MBSA was more apparent at lower concentrations. Thus, 50% of the intracellular bacteria were eliminated at a concentration of 0.2 ,ug of PAS per ml presented as the conjugate, whereas the free form killed only 0.5% of the bacteria.
When infected macrophages were incubated for various periods with PAS (2 ,ug/ml) in the conjugated form, about 55% of bacteria were eliminated within 3 h of exposure. In contrast, exposure to the same concentration of the free drug for the same duration killed only 10% of the bacilli (Fig. 6) 
DISCUSSION
Macrophages from different organs of a variety of animals express high-affinity binding sites which recognize a number of structurally disparate polyanionic macromolecules like acetylated low-density lipoprotein, fucoidin, polyinosinic acid, and MBSA. Binding is followed by internalization and lysosomal degradation of the protein ligands (2, 10). The determinants for recognition and uptake of such polyanionic macromolecules, including MBSA, are present primarily on macrophages (2, 3, 10, 17) and are referred to generically as scavenger receptors which may comprise several distinct molecular species (13, 19, 23) .
This receptor system is beginning to find applications in drug delivery research. Thus, previous work from our laboratory has shown the utility of methotrexate coupled to MBSA for elimination of intracellular amastigotes of Leishmania donovani and L. mexicana amazonensis in macrophages (3, 15) . Similar results have been obtained by using acetylated low-density lipoprotein as the vehicle for delivering antileishmanial agents (12) . Also, acetylated low-density lipoprotein-containing lipophilic muramyl tripeptide has been shown to be delivered to macrophages, resulting in enhancement of their tumoricidal activity (21) . In this study, we used MBSA as a homing device to deliver an antimycobacterial agent, PAS, selectively to macrophages with the expectation that uptake, followed by lysosomal degradation of the PAS-MBSA conjugate, would lead to intracellular release of a pharmacologically active form of the drug, as in our previous studies with conjugates of methotrexate with MBSA.
We conjugated PAS with MBSA by using a water-soluble carbodiimide and determined whether the (Fig. 2) , indicating that the drug conjugate was recognized by MBSA receptors. At 37°C, the radiolabeled drug conjugate was efficiently taken up and degraded by mouse peritoneal macrophages with saturation kinetics (Fig. 3 and 4) . Both MBSA and unlabeled PAS-MBSA effectively competed for uptake and degradation of [125I]PAS-MBSA (data not shown). Conjugation of PAS with MBSA significantly increased the antimycobacterial efficacy of the drug. The conjugated drug at low concentrations was nearly 100-fold as effective as the free drug (Fig. 5) . Over a 5-h period, an average of about 17% of the bacteria were eliminated per h by the PAS-MBSA conjugate (2 ,ug of PAS per ml) but only 2.5% of the bacilli were killed per h by the same concentration of free PAS (Fig. 6) release of a pharmacologically active form of the drug, which effectively eliminated the mycobacteria residing in the infected macrophages.
Thus, we have shown that it is possible to increase the antimycobacterial efficacy of PAS through conjugation of the drug to MBSA. We have also shown that the polyanion receptor system known to be present primarily on cells of macrophage lineage (2, 10, 17) mediates delivery of the conjugate to the macrophages. The efficiency of this receptor system appears to be primarily responsible for an increase in the effective concentration of the antitubercular agent within macrophages. Inasmuch as macrophages are the primary cell type in which various pathogenic mycobacteria reside and proliferate, the receptor-mediated mode of drug delivery to 
